Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis

CORC > 厦门大学 > 数学科学－已发表论文

	Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis
	Li, X-J ; Yu, Y-X ; Liu, C-Q ; Zhang, W. ; Zhang, H-J ; Yan, B. ; Wang, L-Y ; Yang, S-Y ; Zhang, S-H ; Zhang W(张文)
刊名	http://dx.doi.org/10.1111/j.1365-2265.2010.03917.x
	2011-03
关键词	INSULIN-SENSITIZING AGENTS PLACEBO-CONTROLLED TRIAL DIABETES-MELLITUS MOLECULAR-MECHANISMS HOMOCYSTEINE LEVELS CLOMIPHENE CITRATE RESISTANT WOMEN ANDROGEN LEVELS SERUM ANDROGEN LEAN PATIENTS
英文摘要	P>Objectives Insulin-sensitizing drugs (ISDs) have been advocated for the long-term treatment of polycystic ovary syndrome (PCOS). It is therefore important to compare the efficacy and safety of ISDs such as metformin and thiazolidinediones (TZDs) for the treatment of this syndrome. Methods A meta-analysis to assess the effectiveness and safety of metformin vs TZDs (including pioglitazone and rosiglitazone) in the treatment of PCOS was conducted, using MEDLINE (1966-May 2010) and EMBASE (1988-May 2010) to select randomized controlled trials comparing clinical, hormonal and metabolic results. Results Ten trials were included. TZDs were superior to metformin in reducing serum levels of free testosterone (P = 0 center dot 03) and dehydroepiandrosterone sulfate (DHEA) (P = 0 center dot 002) after 3 months treatment. Decreases in triglyceride levels were more pronounced with metformin after 6 months (P < 0 center dot 0001). Decreases in body mass index (BMI) were greater with metformin treatment as assessed at 3 and 6 months (P < 0 center dot 00001). There were no significant between-group differences concerning improvements in ovulation, pregnancy rate, menstrual patterns or insulin sensitivity, or changes in serum levels of androstenedione, luteinizing hormone, follicle-stimulating hormone, total cholesterol, low-density lipoprotein C or insulin. Metformin caused a significantly higher incidence of side effects such as nausea, diarrhoea and abdominal cramping (P < 0 center dot 00001). Significant between-study heterogeneity was detected for several variables assessed. Conclusions The findings from this meta-analysis do not indicate that metformin is superior to TZD's for the treatment of PCOS or vice versa. Between studies, heterogeneity was a major confounder. A large scale, well-designed, randomized, controlled trial is needed to further address this issue.
语种	英语
内容类型	期刊论文
源URL	[http://dspace.xmu.edu.cn/handle/2288/66238]
专题	数学科学－已发表论文
推荐引用方式 GB/T 7714	Li, X-J,Yu, Y-X,Liu, C-Q,et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis[J]. http://dx.doi.org/10.1111/j.1365-2265.2010.03917.x,2011.
APA	Li, X-J.,Yu, Y-X.,Liu, C-Q.,Zhang, W..,Zhang, H-J.,...&张文.(2011).Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.http://dx.doi.org/10.1111/j.1365-2265.2010.03917.x.
MLA	Li, X-J,et al."Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis".http://dx.doi.org/10.1111/j.1365-2265.2010.03917.x (2011).